About Farapulse
Farapulse is a company based in Menlo Park (United States) founded in 2014. Farapulse has raised $36.3 million across 6 funding rounds from investors including Boston Scientific, European Union and F-Prime Capital. Farapulse offers products and services including FARAPULSE PFA System. Farapulse operates in a competitive market with competitors including Kardium, Argá Medtech, Adagio Medical, Affera and Field Medical, among others.
- Headquarter Menlo Park, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Boston Scientific Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$36.3 M (USD)
in 6 rounds
-
Latest Funding Round
$2.14 M (USD), Grant
Mar 01, 2021
-
Investors
Boston Scientific
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Farapulse
Farapulse offers a comprehensive portfolio of products and services, including FARAPULSE PFA System.
Uses electrical pulses to treat atrial fibrillation by isolating pulmonary veins safely.
Funding Insights of Farapulse
Farapulse has successfully raised a total of $36.3M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $2.14 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Farapulse
Farapulse has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Boston Scientific, European Union and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Wide range of medical devices
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Farapulse
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Farapulse
Investment portfolio details for Farapulse
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Farapulse
Detailed financials for Farapulse
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Farapulse Comparisons
Peer comparison for Farapulse
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Farapulse
Farapulse operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kardium, Argá Medtech, Adagio Medical, Affera and Field Medical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Atrial fibrillation ablation devices are developed by Kardium.
|
|
| Locked | Locked | Locked |
Medical devices for cardiac arrhythmias are developed by Argá Medtech.
|
|
| Locked | Locked | Locked |
Cardiovascular therapies are developed by Adagio Medical in stealth mode.
|
|
| Locked | Locked | Locked |
Devices for treating heart rhythm disorders are developed.
|
|
| Locked | Locked | Locked |
Pulsed electric field ablation devices for heart arrhythmias are developed.
|
Detailed competitors of Farapulse
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Farapulse
Complete news archive for Farapulse
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Farapulse
Farapulse was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Farapulse is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Farapulse is a funded company, having raised a total of $36.3M across 6 funding rounds to date.
Farapulse was founded in 2014 and is based in Menlo Park, United States. Operations focus on the medical device sector, specifically cardiac ablation using pulsed field ablation techniques. The flagship product, ENDO FARAWAVE, consists of a percutaneous catheter designed to produce transmural and contiguous lesions on the endocardium. Another device, EPI FARAONE, is intended for creating lesions around pulmonary veins.
Farapulse's top competitors include Kardium, Adagio Medical and Field Medical.
Farapulse offers FARAPULSE PFA System.
Farapulse has 3 investors. Key investors include Boston Scientific, European Union, and F-Prime Capital.